Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration

Retina

Volumn 30, Issue 9, 2010, Pages 1420-1425

  Ach, Thomas ^a   Hoeh, Alexandra E ^a   Ruppenstein, Mira ^a   Kretz, Florian T A ^a   Dithmar, Stefan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

age related macular degeneration; bevacizumab; pigment epithelium detachment; vascularized,PED

Indexed keywords

BEVACIZUMAB;

AGED; ARTICLE; CLINICAL ARTICLE; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; RETREATMENT; RETROSPECTIVE STUDIES; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 78049296919     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181d87e97     Document Type: Article

References (18)

1. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113: 363-372.
2. Casswell AG, Kohen D, Bird AC. Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol 1985;69:397-403. (Pubitemid 15059051)
3. Pauleikhoff D, Loffert D, Spital G, et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol 2002;240:533-538. (Pubitemid 36097080)
4. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neo-vascular age-related macular degeneration. Retina 2006;26: 495-511. (Pubitemid 44620390)
5. Axer-Siegel R, Ehrlich R, Avisar I, et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neovascular age-related macular degeneration with pigment epithelium detachment. Ophthalmic Surg Lasers Imaging 2006;37:455-461. (Pubitemid 44902463)
6. Jonas JB, Strueven V, Kamppeter BA, Harder B, Spandau UH, Schlichtenbrede F. Visual acuity change after intravitreal tri-amcinolone in various types of exudative age-related macular degeneration. J Ocul Pharmacol Ther 2006;22:370-376. (Pubitemid 44706530)
7. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularisation secondary to age-related macular degeneration. Retina 2006;26:383-390. (Pubitemid 44197628)
8. Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 2007;27:445-450. (Pubitemid 46624284)
9. Joeres S, Kaplowitz K, Brubaker JW, et al. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration. Ophthalmology 2008;115:347-354. (Pubitemid 351163358)
10. Ladas ID, Kotsolis Al, Papakostas TD, Rouvas AA, Karagi-annis DA, Vergados I. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Retina 2007; 27:891-896. (Pubitemid 47479383)
11. Pedersen KB, Sjølie AK, Møller F. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients. Acta Ophthalmol Scand 2008 Dec 16 [Epub ahead of print].
12. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439-444. (Pubitemid 46624283)
13. Jonas JB, Libondi T, Ihloff AK, et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol 2007;85:563-565. (Pubitemid 47163119)
14. Lazic R, Gabric N, Dekaris I, Sarić B, Gavrić M. Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration. Coll Antropol 2007;31(suppl 1):77-81.
15. Axer-Siegel R, Ehrlich R, Rosenblatt I, et al. Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol 2004;122:453-459. (Pubitemid 38456279)
16. Furino C, Boscia F, Recchimurzo N, et al. Intravitreal bevacizumab for treatment-naive subfoveal occult choroidal neovascularization in age-related macular degeneration. Acta Ophthalmol 2009;87:404-407.
17. Yannuzzi LA, Hope-Ross M, Slakter JS, et al. Analysis of vascularized pigment epithelial detachments using indocya-nine green videoangiography. Retina 1994;14:99-113. (Pubitemid 24195739)
18. Chan CK, Meyer CH, Gross JG, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007;27: 541-551 (Pubitemid 46905143)